Overcoming Resistance in EGFR-Mutant Cancers: A Comprehensive Review of Inhibitor Evolution and SAR-Based Design.

The epidermal growth factor receptor (EGFR) is a key target in cancer therapy, mainly in non-small cell lung cancer (NSCLC). Though, the efficacy of EGFR-targeted therapies is limited by the development of resistance. This comprehensive review detail…

Preview only. Read the full abstract at the source